If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
Adverse events were consistent with valbenazine’s established safety profile
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
Subscribe To Our Newsletter & Stay Updated
